OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Nordquist on Matching Patients to Clinical Trials

January 15th 2020

Luke Nordquist, MD, FACP, discusses matching patients with clinical trials in oncology.

Dr. Rampal on Unmet Needs in Myelofibrosis and Polycythemia Vera

January 15th 2020

Raajit K. Rampal, MD, PhD, discusses unmet needs in the treatment of patients with myelofibrosis and polycythemia vera.

Dr. Woyach on Ongoing Research With BTK Inhibitors in CLL

January 14th 2020

Jennifer Woyach, MD, associate professor, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center–James, discusses ongoing research with BTK inhibitors in chronic lymphocytic leukemia (CLL).

Dr. Martin on Treating First Relapse in Multiple Myeloma

January 14th 2020

Thomas G. Martin, MD, clinical professor of medicine, Adult Leukemia and Bone Marrow Transplantation Program, associate director, Myeloma Program, University of California, San Francisco, and co-leader, Hematopoietic Malignancies Program, Helen Diller Family Comprehensive Cancer Center, discusses the management of first relapse in patients with multiple myeloma.

Dr. Lockhart on Strategies for Targeting the RAS/RAF/MEK/ERK Pathway in CRC

January 14th 2020

A. Craig Lockhart, MD, MHS, professor and associate director for Regional and Strategic Clinical Research Affiliations, Sylvester Comprehensive Cancer Center, University of Miami Health System, discusses investigational strategies targeting the RAS/RAF/MEK/ERK pathway in colorectal cancer (CRC).

Dr. Gerds on Future Treatment of Patients With Myeloproliferative Neoplasms

January 14th 2020

Aaron Gerds, MD, discusses the future treatment of patients with myeloproliferative neoplasms through the use of JAK-STAT pathway.

Addressing Fatigue as an Adverse Event in Ovarian and Uterine Cancers

January 14th 2020

Hanneke Poort, PhD, discusses research regarding fatigue as an adverse event in patients with gynecologic cancer.

Dr. Rohs on the Use Liquid Biopsies in Lung Cancer

January 14th 2020

Nicholas C. Rohs, MD, assistant professor of medicine, hematology, and medical oncology, Icahn School of Medicine, Mount Sinai, discusses the use of liquid biopsies in lung cancer.

Dr. Aoun on Imaging Modalities in Prostate Cancer

January 14th 2020

Hussein Aoun, MD, a radiologist at Barbara Ann Karmanos Cancer Institute, discusses the imaging modalities that are currently being used in prostate cancer and how they compare with conventional imaging modalities.

Dr. Goy on Preliminary Data With Ibrutinib/Venetoclax in Relapsed/Refractory MCL

January 14th 2020

Andre H. Goy, MD, MS, chief, Division of Lymphoma, chairman and director, John Theurer Cancer Center, discusses preliminary data with the combination of ibrutinib (Imbruvica) and venetoclax (Venclexta) in relapsed/refractory mantle cell lymphoma (MCL).

Dr. Allen on Treatment Options in Advanced-Stage Hodgkin Lymphoma

January 13th 2020

Pamela Blair Allen, MD, MSc, discusses treatment options in advanced-stage Hodgkin lymphoma.

Dr. Shah on the Utility of MRD in Frontline Multiple Myeloma

January 13th 2020

Nina Shah, MD, discusses the utility of minimal residual disease in frontline multiple myeloma.

Dr. Schlumbrecht on the Role of Surgical Resection in Uterine Leiomyosarcoma

January 13th 2020

Matthew P. Schlumbrecht, MD, discusses the role of surgical resection in uterine leiomyosarcoma.

Dr. Coleman on Next Treatment Steps for Patients With Ovarian Cancer

January 13th 2020

Robert L. Coleman, MD, discusses the next steps of treatment for patients with high-grade serous ovarian cancer.

Dr. Janjigian on Data With Atezolizumab/Bevacizumab Combo in HCC

January 11th 2020

Yelena Y. Janjigian, MD, discusses the improvement in efficacy and toxicity with patients with hepatocellular carcinoma who are treated with bevacizumab and atezolizumab when compared with sorafenib.

Dr. Sznol on Immune-Related Toxicities in Melanoma

January 11th 2020

Mario Sznol, MD, discusses the adverse events that can occur from nivolumab in combination with ipilimumab for patients with melanoma.

Dr. Arellano on Managing Older Patients With AML

January 11th 2020

Martha L. Arellano, MD, discusses the management of older patients with acute myeloid leukemia.

Dr. Berger on Frontline Treatment Options in Newly Diagnosed Advanced Ovarian Cancer

January 11th 2020

Jessica Layne Berger, MD, discusses the frontline treatment options in newly diagnosed ovarian cancer.

Dr. Bochner on Standardizing Molecular Profiling in Bladder Cancer

January 11th 2020

Bernard H. Bochner, MD, FACS, discusses the potential standardization of molecular profiling in bladder cancer.

Dr. Burris on the Incorporation of Biosimilars in Oncology

January 10th 2020

Howard "Skip" A. Burris, III, MD, chief medical officer and president, Clinical Operations, Sarah Cannon Research Institute, 2019 ASCO president-elect, and a 2014 Giant of Cancer Care® in Drug Development, discusses the incorporation of biosimilars in oncology.